Explore stories from Atlantic Canada.
Watch onFRANKFURT - The CEO of Germany's Merck KGaA said the company's experimental multiple sclerosis drug can be a"blockbuster", an industry term for annual sales that exceed $1 billion, even after concerns emerged that it may cause liver damage.
At the time, the company said the U.S. Food and Drug Administration had cited laboratory results suggesting drug-induced liver injury, but the two affected patients had no symptoms and did not require any medical intervention. "The readout of our Phase 3 study is going to happen in December," she added of the pivotal study in the clinical trials process.
The company, which is holding a capital markets day at its Darmstadt headquarters on Thursday, had previously guided for initial results from the trial, typically the final stage before seeking approval, would be available by the end of the year.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
LETTER: Abandoned spots in historic N.L. fishing villagesExplore stories from Atlantic Canada.
Lire la suite »
State Street profit beats estimates as fee income, assets under management riseExplore stories from Atlantic Canada.
Lire la suite »
US SEC set to propose limits on brokerage trading rebatesExplore stories from Atlantic Canada.
Lire la suite »
Stellantis aims to rival Ford in commercial vehicles with sales growthExplore stories from Atlantic Canada.
Lire la suite »